Filament Health Corp. announced approval from the United States Food and Drug Administration (FDA) for two clinical trials at leading American research institutions studying the effects of PEX010, Filament's botanical psilocybin drug candidate, for mental health conditions including cancer-related anxiety and depression. The clinical trial at the University of Washington School of Medicine is studying PEX010 for the treatment of cancer- related anxiety in patients with metastatic cancer.

Evidence from a large body of scientific evidence from psychosocial group interventions for cancer patients without psychedelics suggests that the benefits of group therapy plus psilocybin could be substantial. The clinical trial is examining whether the benefits of psilocybin-assisted therapy can be realized in a group model. The trial is underway and has already dosed 5 patients.

The clinical trial at theUniversity of California, Los Angeles (UCLA)'s Semel Institute for Neuroscience and Human Behavioral will examine the effects of joining psilocybin treatment with cognitive-behavioural therapy (CBT) for patients with depression. The trial, led by Dr. Marc Weintraub, PhD, Assistant Professor of Psychiatry, will study the combination of the two treatments as it is believed that psilocybin may help facilitate the success of CBT because it encourages greater cognitive flexibility and behavioural motivation.